Eagle Pharmaceuticals (EGRX) announced that its Board of Directors has adopted a limited duration stockholder rights agreement, effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company’s stockholders to have the opportunity to realize the long-term value of their investment. The Rights Plan is intended to reduce the likelihood that any person or group gains control of the Company through open market accumulation of the Company’s common stock or other means and thereby potentially disadvantaging the interests of the Company’s stockholders without appropriately compensating all stockholders or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of the Company and its stockholders.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EGRX:
- Eagle Pharmaceuticals Navigates Financial Uncertainty and Defaults
- Eagle Pharmaceuticals says in default under credit agreement
- Eagle Pharmaceuticals delays annual report on Form 10-K filing
- Eagle Pharmaceuticals commences review to evaluate range of alternatives
- Eagle Pharmaceuticals sees ‘one or more’ material weaknesses